Get started
Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Teva Pharmaceutical Industries Limited



Key stats


Market capitalization
‪48.49 B‬ USDLarge cap
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
60.99
Basic EPS (TTM)
0.73 USD
Net income (FY)
‪1.53 B‬ USD
Revenue (FY)
‪18.75 B‬ USD
Shares float
‪1.11 B‬
Beta (1Y)
−0.21

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪33.35 K‬
Change (1Y)
‪−2.82 K‬−7.80%
Revenue / Employee (1Y)
‪562.34 K‬ USD
Net income / Employee (1Y)
‪45.77 K‬ USD

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Generic
CEO
Richard Francis
Website
tevapharm.com
Headquarters
Tel Aviv
Founded
1901
IPO date
Jan 1, 1951
ISIN
IL0006290147
FIGI
BBG000HD3FM1
Identifiers
ISIN IL0006290147
CFI code
ESVUFR
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral

Analyst rating


An aggregate view of professional's ratings.
Neutral
Neutral
Neutral

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


6.473% YTM
Maturity dateOct 1, 2046
Coupon4.10% (Fixed)
5.998% YTM
Maturity dateJan 16, 2037
Coupon5.75% (Fixed)
5.937% YTM
Maturity dateFeb 1, 2036
Coupon6.15% (Fixed)
5.822% YTM
Maturity dateJan 16, 2034
Coupon5.50% (Fixed)
5.784% YTM
Maturity dateDec 1, 2032
Coupon6.00% (Fixed)
5.630% YTM
Maturity dateJan 16, 2032
Coupon5.25% (Fixed)
5.628% YTM
Maturity dateDec 1, 2030
Coupon5.75% (Fixed)
4.707% YTM
Maturity dateSep 16, 2036
Coupon4.63% (Fixed)
4.423% YTM
Maturity dateMar 16, 2033
Coupon4.25% (Fixed)
4.324% YTM
Maturity dateJun 1, 2031
Coupon4.13% (Fixed)
4.005% YTM
Maturity dateOct 15, 2028
Coupon1.63% (Fixed)

See all TEVA bonds 

ETFs holding the stock


VXUS
Vanguard Total International Stock ETF
Weight0.10%
Market value‪682.02 M‬
VEA
Vanguard FTSE Developed Markets ETF
Weight0.14%
Market value‪450.07 M‬
IEFA
iShares Core MSCI EAFE ETF
Weight0.19%
Market value‪364.00 M‬
KSM.F74
KSM ETF (4A) TA-125
Weight6.50%
Market value‪227.22 M‬
EFA
iShares MSCI EAFE ETF
Weight0.22%
Market value‪171.80 M‬
KSM.F59
KSM ETF (4A) TA-35 Units
Weight8.47%
Market value‪144.82 M‬
TCH.F2
Tachlit SAL (40) TA 125 IL
Weight6.97%
Market value‪132.93 M‬
ANLT.F3
ATF ETF (4A) TA 125 IL
Weight6.91%
Market value‪114.12 M‬
HRL.F2
Harel Sal (4A) TA 125
Weight6.91%
Market value‪114.12 M‬
SCHF
Schwab International Equity ETF
Weight0.17%
Market value‪112.56 M‬
MTF.F19
MTF SAL (4A) TA-125 IL
Weight6.57%
Market value‪110.09 M‬

Explore more ETFs 

Frequently asked questions


The current price of TEVA is 41.50 USD — it has increased by 0.95% in the past 24 hours. Watch Teva Pharmaceutical Industries Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Teva Pharmaceutical Industries Limited stocks are traded under the ticker TEVA.
TEVA stock has risen by 3.18% compared to the previous week, the month change is a 6.36% rise, over the last year Teva Pharmaceutical Industries Limited has showed a 108.96% increase.
We've gathered analysts' opinions on Teva Pharmaceutical Industries Limited future price: according to them, TEVA price has a max estimate of 54.74 USD and a min estimate of 42.80 USD. Watch TEVA chart and read a more detailed Teva Pharmaceutical Industries Limited stock forecast: see what analysts think of Teva Pharmaceutical Industries Limited and suggest that you do with its stocks.
TEVA reached its all-time high on Jul 28, 2015 with the price of 72.31 USD, and its all-time low was 0.06 USD and was reached on Nov 19, 1984. View more price dynamics on TEVA chart.
See other stocks reaching their highest and lowest prices.
TEVA stock is 1.81% volatile and has beta coefficient of −0.21. Track Teva Pharmaceutical Industries Limited stock price on the chart and check out the list of the most volatile stocks — is Teva Pharmaceutical Industries Limited there?
Today Teva Pharmaceutical Industries Limited has the market capitalization of ‪48.08 B‬, it has decreased by −1.55% over the last week.
Yes, you can track Teva Pharmaceutical Industries Limited financials in yearly and quarterly reports right on TradingView.
Teva Pharmaceutical Industries Limited is going to release the next earnings report on Nov 3, 2026. Keep track of upcoming events with our Earnings Calendar.
TEVA earnings for the last quarter are 0.02 USD per share, whereas the estimation was 0.05 USD resulting in a −60.67% surprise. The estimated earnings for the next quarter are 0.72 USD per share. See more details about Teva Pharmaceutical Industries Limited earnings.
Teva Pharmaceutical Industries Limited revenue for the last quarter amounts to ‪4.28 B‬ USD, despite the estimated figure of ‪4.08 B‬ USD. In the next quarter, revenue is expected to reach ‪4.23 B‬ USD.
TEVA net income for the last quarter is ‪−572.70 M‬ USD, while the quarter before that showed ‪365.74 M‬ USD of net income which accounts for 0.00% change. Track more Teva Pharmaceutical Industries Limited financial stats to get the full picture.
No, TEVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 17, 2026, the company has ‪33.35 K‬ employees. See our rating of the largest employees — is Teva Pharmaceutical Industries Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Teva Pharmaceutical Industries Limited EBITDA is ‪4.61 B‬ USD, and current EBITDA margin is 28.97%. See more stats in Teva Pharmaceutical Industries Limited financial statements.
Like other stocks, TEVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Teva Pharmaceutical Industries Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Teva Pharmaceutical Industries Limited technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Teva Pharmaceutical Industries Limited stock shows the strong buy signal. See more of Teva Pharmaceutical Industries Limited technicals for a more comprehensive analysis.